18F-MK-6240 PET for early and late detection of neurofibrillary tangles
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the criteria for the neuropathological diagnosis of Alzheimer’s disease. It is expected that Braak staging using brain imaging can stratify living individuals according to their individual patterns of tau deposition, which may prove crucial for clinical trials and practice. However, previous studies using the first-generation tau PET agents have shown a low sensitivity to detect tau pathology in areas corresponding to early Braak histopathological stages (∼20% of cognitively unimpaired elderly with tau deposition in regions corresponding to Braak I–II), in contrast to ∼80–90% reported in post-mortem cohorts. Here, we tested whether the novel high affinity tau tangles tracer 18F-MK-6240 can better identify individuals in the early stages of tau accumulation. To this end, we studied 301 individuals (30 cognitively unimpaired young, 138 cognitively unimpaired elderly, 67 with mild cognitive impairment, 54 with Alzheimer’s disease dementia, and 12 with frontotemporal dementia) with amyloid-β 18F-NAV4694, tau 18F-MK-6240, MRI, and clinical assessments. 18F-MK-6240 standardized uptake value ratio images were acquired at 90–110 min after the tracer injection. 18F-MK-6240 discriminated Alzheimer’s disease dementia from mild cognitive impairment and frontotemporal dementia with high accuracy (∼85–100%). 18F-MK-6240 recapitulated topographical patterns consistent with the six hierarchical stages proposed by Braak in 98% of our population. Cognition and amyloid-β status explained most of the Braak stages variance (P < 0.0001, R2 = 0.75). No single region of interest standardized uptake value ratio accurately segregated individuals into the six topographic Braak stages. Sixty-eight per cent of the cognitively unimpaired elderly amyloid-β-positive and 37% of the cognitively unimpaired elderly amyloid-β-negative subjects displayed tau deposition, at least in the transentorhinal cortex (Braak I). Tau deposition solely in the transentorhinal cortex was associated with an elevated prevalence of amyloid-β, neurodegeneration, and cognitive impairment (P < 0.0001). 18F-MK-6240 deposition in regions corresponding to Braak IV–VI was associated with the highest prevalence of neurodegeneration, whereas in Braak V–VI regions with the highest prevalence of cognitive impairment. Our results suggest that the hierarchical six-stage Braak model using 18F-MK-6240 imaging provides an index of early and late tau accumulation as well as disease stage in preclinical and symptomatic individuals. Tau PET Braak staging using high affinity tracers has the potential to be incorporated in the diagnosis of living patients with Alzheimer’s disease in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“%) had 18F-MK6240 tau tangle deposition consistent with the stereotypical patterns proposed by Braak in post-mortem cohorts, from the transentorhinal to primary sensory cortices (Braak and Braak, 1991).”
BackgroundMethodResultInfluentialBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“Braak stages were based on the anatomical brain regions proposed by Braak (Braak and Braak, 1991, 1997; Braak et al., 2006; Braak et al., 2011) as follows: Braak I (transentorhinal), Braak II (entorhinal and hippocampus), Braak III (amygdala, parahippocampal gyrus, fusiform gyrus, lingual gyrus), Braak IV (insula, inf…”
MethodMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“, 2011), which was named primary age-related tauopathy (Crary et al., 2014).”
BackgroundPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972
Research works printed but not linked: 23
- Betthauser, 2019, In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from alzheimer disease dementia to young controls, J Nucl Med, 60, 93, 10.2967/jnumed.118.209650 · DOI · Paper page
- Betthauser, 2020, Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age, Brain, 143, 320, 10.1093/brain/awz378 · DOI · Paper page
- Cselenyi, 2012, Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand, J Nucl Med, 53, 415, 10.2967/jnumed.111.094029 · DOI · Paper page
- Guillozet, 2003, Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment, Arch Neurol, 60, 729, 10.1001/archneur.60.5.729 · DOI · Paper page
- Harada, 2015, 18[F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease, Eur J Nucl Med Mol Imaging, 42, 1052, 10.1007/s00259-015-3035-4 · DOI
- Heutink, 2000, Untangling tau-related dementia, Hum Mol Genet, 9, 979, 10.1093/hmg/9.6.979 · DOI
- Kimura, 2015, PET quantification of tau pathology in human brain with 11C-PBB3, J Nucl Med, 56, 1359, 10.2967/jnumed.115.160127 · DOI · Paper page
- Klein, 2012, 101 labeled brain images and a consistent human cortical labeling protocol, Front Neurosci, 6, 171, 10.3389/fnins.2012.00171 · DOI · Paper page
- Koga, 2017, Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology, Mov Disord, 32, 884, 10.1002/mds.27013 · DOI
- Kulason, 2019, Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment, Neuroimage Clin, 21, 101617, 10.1016/j.nicl.2018.101617 · DOI
- Lowe, 2018, Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia, Brain, 141, 271, 10.1093/brain/awx320 · DOI · Paper page
- Mathotaarachchi, 2016, VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis, Front Neuroinform, 10, 20, 10.3389/fninf.2016.00020 · DOI
- Mazziotta, 1995, A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM), Neuroimage, 2, 89, 10.1006/nimg.1995.1012 · DOI · Paper page
- Neary, 2005, Frontotemporal dementia, Lancet Neurol, 4, 771, 10.1016/S1474-4422(05)70223-4 · DOI · Paper page
- Ng, 2017, Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain, Alzheimers Res Ther, 9, 25, 10.1186/s13195-017-0253-y · DOI · Paper page
- Ossenkoppele, 2018, Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer disease vs other neurodegenerative disorders, JAMA, 320, 1151, 10.1001/jama.2018.12917 · DOI · Paper page
- Pascoal, 2018, Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease, Eur J Nucl Med Mol Imaging, 45, 1021, 10.1007/s00259-018-3933-3 · DOI
- Pascoal, 2018, In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240, Alzheimers Res Ther, 10, 74, 10.1186/s13195-018-0402-y · DOI · Paper page
- Pontecorvo, 2017, Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition, Brain, 140, 748
- Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease, . Ann Neurol, 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
- Snowden, 2011, The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships, Brain, 134, 2478, 10.1093/brain/awr189 · DOI · Paper page
- Tward, 2017, Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry, Alzheimers Dement, 9, 41
- Villemagne, 2018, Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions, Nat Rev Neurol, 14, 225, 10.1038/nrneurol.2018.9 · DOI · Paper page
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationTau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Microglial activation and tau propagate jointly across Braak stages
Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490
Self-citationOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu-Gaya, L., Lantero-Rodriguez, J., Pascoal, T. A., Suárez-Calvet, M., Rosa-Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 329
Self-citationBellaver, B., Povala, G., Ferreira, P. C. L., Ferrari-Souza, J. P., Leffa, D. T., Lussier, F. Z., Benedet, A. L., Ashton, N. J., Triana-Baltzer, G., Kolb, H. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02380-x · Cited by 319
Self-citationBiomarker modeling of Alzheimer’s disease using PET-based Braak staging
Therriault, J., Pascoal, T. A., Lussier, F. Z., Tissot, C., Chamoun, M., Bezgin, G., Servaes, S., Benedet, A. L., Ashton, N. J., Karikari, T. K., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00204-0 · Cited by 308
Self-citationEarly stages of tau pathology and its associations with functional connectivity, atrophy and memory
Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain · doi:10.1093/brain/awab114 · Cited by 240
“While tau begins to accumulate in MTL regions in the anteriortemporal system, it can be increasingly seen in regions in the posterior-medial system with disease progression.(11,12) Furthermore, tau pathology is tightly linked to atrophy and future neurodegeneration, and both are associated with cognitive impairment, w…”
BackgroundCerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184
Self-citationTau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00405-1 · Cited by 122
Self-citationCurrent trends in blood biomarker detection and imaging for Alzheimer’s disease
Hu, S., Yang, C., & Luo, H. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114278 · Cited by 84
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Self-citationMalarte, M.-L., Gillberg, P.-G., Kumar, A., Bogdanovic, N., Lemoine, L., & Nordberg, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01875-2 · Cited by 67
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
White matter abnormalities and cognition in aging and Alzheimer disease
Peter, C., Sathe, A., Shashikumar, N., Pechman, K. R., Workmeister, A. W., Jackson, T. B., Huo, Y., Mukherjee, S., Mez, J., Dumitrescu, L. C., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1601 · Cited by 59
Appleton, J., Finn, Q., Zanotti-Fregonara, P., Yu, M., Faridar, A., Nakawah, M. O., Zarate, C., Carrillo, M. C., Dickerson, B. C., Rabinovici, G. D., et al. (2025) · Brain · doi:10.1093/brain/awae234 · Cited by 58
Association of plasma P-tau181 with memory decline in non-demented adults
Therriault, J., Benedet, A. L., Pascoal, T. A., Lussier, F. Z., Tissot, C., Karikari, T. K., Ashton, N. J., Chamoun, M., Bezgin, G., Mathotaarachchi, S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab136 · Cited by 56
Self-citationVanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Self-citationCharacterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
Malarte, M.-L., Nordberg, A., & Lemoine, L. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05035-y · Cited by 41
“A recent study using (18)F-MK6240 also showed that 18F-MK6240 was able to discriminate between early and late stages of the disease in vivo [26].”
BackgroundMachine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
Smith, R., Hägerström, D., Pawlik, D., Klein, G., Jögi, J., Ohlsson, T., Stomrud, E., & Hansson, O. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1323 · Cited by 33
Alzheimer’s disease: From basic science to precision medicine approach
Forloni, G. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000079 · Cited by 33
Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
Rullmann, M., Brendel, M., Schroeter, M. L., Saur, D., Levin, J., Perneczky, R. G., Tiepolt, S., Patt, M., Mueller, A., Villemagne, V. L., et al. (2022) · Biomolecules · doi:10.3390/biom12030458 · Cited by 29
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease
Macedo, A. C., Durço, D. F. P. A., Tissot, C., Therriault, J., Vilela de Faria, A. O., Aumont, É., Servaes, S., Rahmouni, N., Fernandez-Arias, J., Wang, Y.-T., et al. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.15 · Cited by 26
“In Pascoal et al. (2020), [ 18 F]MK6240 tau-PET assigned Braak stages showed significant associations with clinical diagnosis (CU, MCI, AD) (r = 0.61, p < 0.0001) in ordinal logistic regressions adjusted for age and gender (25).”
InfluentialSelf-citationDeep learning improves utility of tau PET in the study of Alzheimer's disease
Zou, J., Park, D., Johnson, A., Feng, X., Pardo, M., France, J., Tomljanovic, Z., Brickman, A. M., Devanand, D. P., Luchsinger, J. A., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12264 · Cited by 15
“2 for details), (5) averaging and internal normalization of uptake values.”
Background
Metadata
- Authors
- Pascoal, T. A., Therriault, J., Benedet, A. L., Savard, M., Lussier, F. Z., Chamoun, M., Tissot, C., Qureshi, M. N. I., Kang, M. S., Mathotaarachchi, S., Stevenson, J., Hopewell, R., Massarweh, G., Soucy, J.-P., Gauthier, S., & Rosa-Neto, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-16
- Volume
- 143
- Issue
- 9
- Pages
- 2818-2830
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W3042402214
- Cited by
- 252
- References
- 18
- FWCI
- 21.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31, FRN, 152985)
- Alzheimer's Association (NIRG-12- 92090, NIRP-12-259245)
- Fonds de Recherche du Québec – Santé
- FRQS (2020-VICO-279314)
- Canada Foudation for innovation (34874)
- CFI (34874)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.